Abstract:
Lactams are purified by forming a melt of crude lactam and adding to it sufficiently finely divided solid crude lactam to make a mixture in which the melt forms 50-90% by weight, maintaining the mixture in an adiabatic state and, after melting equilibrium is reached, separating crystals of purified lactam from the mixture. The process is particularly suitable for the purification of lactams having 7-13 ring members. The crude lactam may be subjected to a preliminary treatment with potassium permanganate prior to purification.
Abstract:
The invention provides a process for the production of crystalline ammonium sulfate, wherein the process comprises performing a Beckmann rearrangement reaction, neutralizing the Beckmann rearrangement reaction mixture, separating a first aqueous ammonium sulfate phase and an aqueous ε-caprolactam phase, charging the first ammonium sulfate phase to a first evaporative type crystallization section wherein crystalline ammonium sulfate is obtained, discharging from the first evaporative type crystallization section mother liquor enriched in organic components, extracting the aqueous ε-caprolactam phase to obtain an extracted ε-caprolactam phase and a second aqueous ammonium sulfate phase, discharging the mother liquor that is discharged from the first evaporative type crystallization section and/or the second aqueous ammonium sulfate phase to a second evaporative type crystallization section wherein evaporative type crystallization is performed so that a three-phase system occurs. At least a liquid oily phase is recovered from the three-phase system. The invention further provides a plant suitable to carry out the process of the invention, crystalline ammonium sulfate and a liquid oily phase obtained by the process of the invention.
Abstract:
The present invention relates to a process for purifying caprolactam from solutions of crude caprolactam by a direct treatment with one or more alkaline compounds of polyvalent metals, preferably bivalent and trivalent, without resorting to organic solvent extraction as used in the usual purification process. A further subject of the present invention is a facility devoid of a unit for organic solvent extraction and designed to carry out the caprolactam purification process described herein.
Abstract:
The present invention relates to a process for purifying caprolactam from solutions of cmde caprolactam by a direct treatment with one or more alkaline compounds of polyvalent metals, preferably bivalent and trivalent, without resorting to organic solvent extraction as used in the usual purification process. A further subject of the present invention is a facility devoid of a unit for organic solvent extraction and designed to carry out the caprolactam purification process described herein.
Abstract:
Process for purifying N-alkylpyrrolidones which due to a previous use comprise at least one of the impurities of the formula I or II where R is hydrogen or a C1-C20-alkyl group, wherein a basic compound is added to the N-alkylpyrrolidone to be purified and the temperature of the mixture is at least 80° C. not more than 20 minutes after addition of the basic compound and N-alkylpyrrolidone is distilled off from the mixture obtained.
Abstract:
A method for producing N-vinyl-2-pyrrolidone by crystallization including: controlling a water content in a feed N-vinyl-2-pyrrolidone solution at an inlet of a crystallizer so as to be not lower than 0.7% by weight and not higher than 10% by weight based on the total weight of the N-vinyl-2-pyrrolidone solution; and supplying the feed N-vinyl-2-pyrrolidone solution to a crystallization process.
Abstract:
Novel acyl-urea containing compounds, processes of preparing same, compositions containing same and uses thereof in the treatment of neurological diseases and disorders such as epilepsy, neuropathic pain, bipolar disorder, status epilepticus, chemically-induced convulsions and/or seizure disorders, febrile convulsions conditions, metabolic disturbances and a sustenance withdrawal conditions, are provided. Also provided are uses of these and other acyl-urea containing compounds in the treatment of neurological diseases and disorders.